首页> 外文期刊>Circulation. Heart failure >Wireless Pulmonary Artery Pressure Monitoring Guides Management to Reduce Decompensation in Heart Failure With Preserved Ejection Fraction.
【24h】

Wireless Pulmonary Artery Pressure Monitoring Guides Management to Reduce Decompensation in Heart Failure With Preserved Ejection Fraction.

机译:无线肺动脉压力监测功能可通过保留射血分数降低心力衰竭的代偿性,从而指导管理。

获取原文
获取原文并翻译 | 示例
       

摘要

Background-: No treatment strategies have been demonstrated to be beneficial for the population for patients with heart failure (HF) and preserved ejection fraction (EF).Methods and Results-: The CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients (CHAMPION) trial was a prospective, single-blinded, randomized controlled clinical trial testing the hypothesis that hemodynamically guided HF management decreases decompensation leading to hospitalization. Of the 550 patients enrolled in the study, 119 had left ventricular EF >=40% (average, 50.6%), 430 patients had low left ventricular EF (<40%; average, 23.3%), and 1 patient had no documented left ventricular EF. A microelectromechanical system pressure sensor was permanently implanted in all participants during right heart catheterization. After implant, subjects were randomly assigned in single-blind fashion to a treatment group in whom daily uploaded pressures were used in a treatment strategy for HF management or to a control group in whom standard HF management included weight-monitoring, and pressures were uploaded but not available for investigator use. The primary efficacy end point of HF hospitalization rate >6 months for preserved EF patients was 46% lower in the treatment group compared with control (incidence rate ratio, 0.54; 95% confidence interval, 0.38-0.70; P<0.0001). After an average of 17.6 months of blinded follow-up, the hospitalization rate was 50% lower (incidence rate ratio, 0.50; 95% confidence interval, 0.35-0.70; P<0.0001). In response to pulmonary artery pressure information, more changes in diuretic and vasodilator therapies were made in the treatment group.Conclusions-: Hemodynamically guided management of patients with HF with preserved EF reduced decompensation leading to hospitalization compared with standard HF management strategies.
机译:背景-:尚无治疗策略被证明对心力衰竭(HF)和射血分数(EF)保持患者的人群有益。方法和结果-:CardioMEMS心脏传感器可监测压力以改善NYHA类的结果III型心力衰竭患者(CHAMPION)试验是一项前瞻性,单盲,随机对照临床试验,旨在验证以下假设:血液动力学指导的HF管理可减少代偿失调导致住院。在研究的550位患者中,有119位左心室EF> = 40%(平均50.6%),有430位左心室EF低(<40%;平均值23.3%),有1位患者未记录左心室EF心室EF。在右心导管插入期间,将微机电系统压力传感器永久植入所有参与者中。植入后,将受试者以单盲方式随机分配至治疗组,在该治疗组中将每日上传的压力用于HF管理的治疗策略中,或一个对照组,在该组中,标准HF管理包括体重监测,并上传压力,但不适用于研究人员。与对照组相比,治疗组EF保留的HF住院率> 6个月的主要疗效终点比对照组低46%(发生率,0.54; 95%置信区间,0.38-0.70; P <0.0001)。在平均17.6个月的盲法随访后,住院率降低了50%(发生率,0.50; 95%置信区间,0.35-0.70; P <0.0001)。根据肺动脉压力信息,治疗组在利尿剂和血管舒张剂治疗方面进行了更多改变。结论:与传统的HF治疗策略相比,保留了EF的HF患者的血流动力学指导治疗减少了代偿失调导致的住院治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号